I think this is where BTD makes a difference. If a license deal is with BP, I don’t see them getting 50%, but CYDY would definitely have more leverage in this discussion compared to HIV. BTD is kind of a double edge sword as IMO definitely puts them in the BO crosshairs. I hope they can navigate to maximize shareholder value in whatever course is chosen. FWIW, given how things have played out so far with the RP situation I have confidence the BOD has our best interest in mind.

I could be wrong, but my hope is they license NASH with BP with large upfront payments and keep cancer as you mention. At this point whether they use Syneos for commercialization or establish their own sales force would be interesting. I would think leronlimab will sell itself if cancer works as good as advertised so far.